multiple myeloma
Conditions
Interventions
Thymosin a1 group:No intervention
No thymosin a1 group:No intervention
Sponsors
Department of Hematology, The Third Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients must meet all the following conditions to be selected: 1. Age>=18, regardless of gender 2. a. Patients with newly diagnosed multiple myeloma treated for the first time b. MM patients within+30d -+60d after autologous HSCT transplantation 3. Generally: ECOG score<3 4. No important organ function damage: a. Serum AST, ALT=<3 times the upper normal limit b. Total bilirubin=<3 times the upper limit of normal value c. Serum creatinine=<3 times the upper limit of normal value d. ECG Q-T interval=<450ms
Exclusion criteria
Exclusion criteria: Patients with one of the following conditions cannot be selected: 1. Patients in thymosin a1 group were in the course of infection or anti infection when they first used thymosin a1 2. Patients in thymosin a1 group had known immediate or delayed hypersensitivity reaction history to similar drugs and excipients of the study drug 3. Chronic renal failure requiring hemodialysis or peritoneal dialysis 4. Known or suspected cirrhosis, portal hypertension, chronic jaundice or chronic ascites 5. Human immunodeficiency virus infection 6. History of lung, liver, kidney or small intestine transplantation 7. Pregnancy or breastfeeding 8. Patients who refused to take effective contraceptive measures during the study 9. Due to uncorrectable medical conditions, such as poor tumor control or other end-stage diseases, the patient is not expected to survive for 3 months 10. Participate in other interventional clinical studies at the same time 11. Conditions that other researchers think cannot be included in the group
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total number of infections during observation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of infection;Time to first infection after enrollment;Antibacterial/viral/fungal drug use time;Number of serious infections;Multiple drug resistant bacteria infection times;The average hospitalization days;Infection rate;Infection rate of multi drug resistant bacteria;Objective response rate;Complete response rate;Progression free survival;overall survival;Total hospitalization expenses; | — |
Countries
China
Contacts
Public ContactLiXin
Department of Hematology, The Third Xiangya Hospital of Central South University
Outcome results
None listed